» Articles » PMID: 26715773

Clinical Outcomes and Prognostic Factors in a Cohort of Adults With Cystic Fibrosis: A 7-Year Follow-Up Study

Overview
Journal Respir Care
Publisher Mary Ann Liebert
Specialty Pulmonary Medicine
Date 2015 Dec 31
PMID 26715773
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Due to the heterogeneity of cystic fibrosis (CF), the longer survival observed in cohorts of adult subjects, and inter-population variations, there is a clear need to seek further information about clinical outcomes and prognostic factors in different cohorts of subjects with CF. Our objectives were to evaluate clinical outcomes and prognostic factors in a cohort of adult subjects with CF after a 7-y follow-up period and investigate longitudinal changes in clinical scores, spirometry, 6-min walk test performance, and pulmonary artery systolic pressure as assessed by Doppler echocardiography.

Methods: A cohort of clinically stable subjects (≥16 y old) who were enrolled in an adult CF program in 2004-2005 underwent clinical evaluation. Outcome was classified as good (survival) or poor (survival with lung transplantation or death). In 2011-2012, survivors were re-examined.

Results: Of 40 subjects with CF evaluated in 2004-2005, 32 (80%) survived, 2 (5%) survived with lung transplantation, and 6 (15%) died. Logistic regression analysis showed that a low percent-of-predicted FEV1 was associated with poor outcome. An FEV1 cut-off value of ≤30% and pulmonary artery systolic pressure of ≥42 mm Hg predicted poor outcome with high sensitivity, specificity, and positive and negative predictive values. Deterioration was observed in clinical scores (P = .03), FVC (P = .02), FEV1 (P < .001), distance walked in the 6-min walk test (P = .002), baseline SpO2 (P < .001), and final SpO2 (P < .001).

Conclusions: After 7 y of follow-up, 20% of subjects with CF had a poor outcome. Pulmonary artery systolic pressure of ≥42 mm Hg and FEV1 of ≤30% were the most significant prognostic predictors of poor outcome. Clinical and functional deterioration was observed in survivors.

Citing Articles

Clinimetric properties of field exercise tests in cystic fibrosis: a systematic review.

Corda J, Holland A, Tannenbaum E, Cox N Eur Respir Rev. 2024; 33(174).

PMID: 39694588 PMC: 11653197. DOI: 10.1183/16000617.0142-2024.


Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.

Ramos K, Smith P, McKone E, Pilewski J, Lucy A, Hempstead S J Cyst Fibros. 2019; 18(3):321-333.

PMID: 30926322 PMC: 6545264. DOI: 10.1016/j.jcf.2019.03.002.


Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.

Rubin J, OCallaghan L, Pelligra C, Konstan M, Ward A, Ishak J Ther Adv Respir Dis. 2019; 13:1753466618820186.

PMID: 30803355 PMC: 6366006. DOI: 10.1177/1753466618820186.


Predictors of deterioration of lung function in Polish children with cystic fibrosis.

Olszowiec-Chlebna M, Koniarek-Maniecka A, Stelmach W, Smejda K, Jerzynska J, Majak P Arch Med Sci. 2016; 12(2):402-7.

PMID: 27186187 PMC: 4848371. DOI: 10.5114/aoms.2016.59268.